CN102227501B - 基因治疗载体和胞嘧啶脱氨酶 - Google Patents

基因治疗载体和胞嘧啶脱氨酶 Download PDF

Info

Publication number
CN102227501B
CN102227501B CN200980147509.6A CN200980147509A CN102227501B CN 102227501 B CN102227501 B CN 102227501B CN 200980147509 A CN200980147509 A CN 200980147509A CN 102227501 B CN102227501 B CN 102227501B
Authority
CN
China
Prior art keywords
polypeptide
polynucleotide
sequence
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980147509.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102227501A (zh
Inventor
哈利·E·格鲁贝尔
道格拉斯·乔利
奥马尔·佩雷斯
克里斯托弗·R·洛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suoyuan Biomedical Usa Co ltd
Original Assignee
Tocagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tocagen Inc filed Critical Tocagen Inc
Priority to CN201510505943.4A priority Critical patent/CN105274125A/zh
Publication of CN102227501A publication Critical patent/CN102227501A/zh
Application granted granted Critical
Publication of CN102227501B publication Critical patent/CN102227501B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980147509.6A 2008-09-26 2009-09-26 基因治疗载体和胞嘧啶脱氨酶 Expired - Fee Related CN102227501B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510505943.4A CN105274125A (zh) 2008-09-26 2009-09-26 基因治疗载体和胞嘧啶脱氨酶

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10066608P 2008-09-26 2008-09-26
US61/100,666 2008-09-26
US12061808P 2008-12-08 2008-12-08
US61/120,618 2008-12-08
US18682309P 2009-06-13 2009-06-13
US61/186,823 2009-06-13
PCT/US2009/058510 WO2010045002A2 (en) 2008-09-26 2009-09-26 Gene therapy vectors and cytosine deaminases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510505943.4A Division CN105274125A (zh) 2008-09-26 2009-09-26 基因治疗载体和胞嘧啶脱氨酶

Publications (2)

Publication Number Publication Date
CN102227501A CN102227501A (zh) 2011-10-26
CN102227501B true CN102227501B (zh) 2016-11-16

Family

ID=42060421

Family Applications (4)

Application Number Title Priority Date Filing Date
CN200980147515.1A Expired - Fee Related CN102227503B (zh) 2008-09-26 2009-09-26 重组载体
CN201510505943.4A Pending CN105274125A (zh) 2008-09-26 2009-09-26 基因治疗载体和胞嘧啶脱氨酶
CN201510624987.9A Expired - Fee Related CN105624193B (zh) 2008-09-26 2009-09-26 重组载体
CN200980147509.6A Expired - Fee Related CN102227501B (zh) 2008-09-26 2009-09-26 基因治疗载体和胞嘧啶脱氨酶

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN200980147515.1A Expired - Fee Related CN102227503B (zh) 2008-09-26 2009-09-26 重组载体
CN201510505943.4A Pending CN105274125A (zh) 2008-09-26 2009-09-26 基因治疗载体和胞嘧啶脱氨酶
CN201510624987.9A Expired - Fee Related CN105624193B (zh) 2008-09-26 2009-09-26 重组载体

Country Status (18)

Country Link
US (3) US8722867B2 (enExample)
EP (4) EP2346995B1 (enExample)
JP (6) JP5684130B2 (enExample)
KR (3) KR101870056B1 (enExample)
CN (4) CN102227503B (enExample)
AU (1) AU2009303690B2 (enExample)
BR (1) BRPI0919113A2 (enExample)
CA (1) CA2738472A1 (enExample)
CO (1) CO6362050A2 (enExample)
DK (1) DK2346995T3 (enExample)
EA (2) EA201790824A3 (enExample)
ES (2) ES2706899T3 (enExample)
IL (3) IL211847A (enExample)
MX (3) MX357418B (enExample)
MY (1) MY156333A (enExample)
NZ (1) NZ592070A (enExample)
WO (2) WO2010045002A2 (enExample)
ZA (1) ZA201102115B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018240A1 (en) 1998-10-01 2000-04-06 University Of Southern California Gene delivery system and methods of use
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102227503B (zh) 2008-09-26 2015-10-21 托卡根公司 重组载体
JP5923037B2 (ja) 2009-06-17 2016-05-24 トカジェン インコーポレーテッド 複製可能レトロウイルスベクターの産生細胞
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
CA2803011C (en) 2010-07-16 2019-12-03 Tocagen Inc. Retrovirus detection
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
WO2012058637A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Antisera assays for mlv related viruses in humans and other mammals
CN107488233A (zh) * 2011-06-02 2017-12-19 台北荣民总医院 治疗感染性与恶性疾病的标靶化学治疗药物的形成方法
KR101554678B1 (ko) * 2012-10-19 2015-09-21 영남대학교 산학협력단 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도
WO2014066700A1 (en) 2012-10-25 2014-05-01 Tocagen Inc. Retroviral vector with mini-promoter cassette
JP2016506373A (ja) * 2012-11-15 2016-03-03 エスペランス ファーマシューティカルズ， インコーポレイテッド 卵胞刺激ホルモン（ｆｓｈ）／溶解ドメイン融合コンストラクト及びその作製及び使用の方法
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
EP3008175B1 (en) 2013-06-15 2019-08-07 Tocagen Inc. Immunosuppressive viral like particles based on gammaretrovirus
JP2016526920A (ja) * 2013-08-05 2016-09-08 トカジェン インコーポレーテッド 最適化ａ−バルジを有する組換えベクター
CN103966260A (zh) * 2014-03-07 2014-08-06 山东农业大学 一种基于J亚群禽白血病病毒pol基因保守序列的siRNA重组干扰载体及其制备方法和应用
EP3122884B1 (en) * 2014-03-26 2019-12-25 Tocagen Inc. A retroviral vector having immune-stimulating activity
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
WO2015168102A2 (en) * 2014-04-28 2015-11-05 Board Of Regents, The University Of Texas System Prolonged protein stabilization by resveratrol
CN104557602B (zh) * 2015-01-07 2016-08-17 华东师范大学 三环二萜衍生物及其制备方法、及其在制备抗肿瘤药物中的应用
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11279949B2 (en) 2015-09-04 2022-03-22 Denovo Biopharma Llc Recombinant vectors comprising 2A peptide
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
GB2572716B (en) 2016-11-29 2022-06-22 Articure Co Ltd Gene Therapy Vector System and Prodrug Genes
CN107058314B (zh) * 2016-11-30 2020-09-04 暨南大学 一种启动子及其应用
CA3045665A1 (en) 2016-12-12 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
CA3066253C (en) 2017-06-30 2023-10-31 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
AU2018301701A1 (en) * 2017-07-14 2020-02-27 Elevatebio Technologies, Inc. Encapsulated polynucleotides and methods of use
CN111526777A (zh) 2017-12-27 2020-08-11 爱惜康有限责任公司 缺光环境中的荧光成像
WO2019162521A1 (en) * 2018-02-26 2019-08-29 Ablynx Nv Improved nucleotide sequences encoding peptide linkers
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
CN110396504A (zh) * 2018-04-25 2019-11-01 江苏省原子医学研究所 一种具有肿瘤靶向性的重组痘苗病毒及其制备方法、用途
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
IL292273B2 (en) 2018-08-14 2023-10-01 Inscripta Inc Devices, modules and methods for improved detection of edited sequences in living cells
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020198174A1 (en) 2019-03-25 2020-10-01 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11389066B2 (en) 2019-06-20 2022-07-19 Cilag Gmbh International Noise aware edge enhancement in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US10952619B2 (en) 2019-06-20 2021-03-23 Ethicon Llc Hyperspectral and fluorescence imaging and topology laser mapping with minimal area monolithic image sensor
US20200397245A1 (en) 2019-06-20 2020-12-24 Ethicon Llc Minimizing image sensor input/output in a pulsed fluorescence imaging system
US12126887B2 (en) 2019-06-20 2024-10-22 Cilag Gmbh International Hyperspectral and fluorescence imaging with topology laser scanning in a light deficient environment
US12013496B2 (en) 2019-06-20 2024-06-18 Cilag Gmbh International Noise aware edge enhancement in a pulsed laser mapping imaging system
US11096565B2 (en) 2019-06-20 2021-08-24 Cilag Gmbh International Driving light emissions according to a jitter specification in a hyperspectral, fluorescence, and laser mapping imaging system
US11311183B2 (en) 2019-06-20 2022-04-26 Cilag Gmbh International Controlling integral energy of a laser pulse in a fluorescence imaging system
US12357162B2 (en) 2019-06-20 2025-07-15 Cilag Gmbh International Videostroboscopy of vocal cords with a hyperspectral, fluorescence, and laser mapping imaging system
US11531112B2 (en) 2019-06-20 2022-12-20 Cilag Gmbh International Offset illumination of a scene using multiple emitters in a hyperspectral, fluorescence, and laser mapping imaging system
US11280737B2 (en) 2019-06-20 2022-03-22 Cilag Gmbh International Super resolution and color motion artifact correction in a pulsed fluorescence imaging system
US11012599B2 (en) 2019-06-20 2021-05-18 Ethicon Llc Hyperspectral imaging in a light deficient environment
US11516387B2 (en) 2019-06-20 2022-11-29 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US11237270B2 (en) 2019-06-20 2022-02-01 Cilag Gmbh International Hyperspectral, fluorescence, and laser mapping imaging with fixed pattern noise cancellation
US12440085B2 (en) 2019-06-20 2025-10-14 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed laser mapping imaging system
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
KR102281858B1 (ko) 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
WO2021102059A1 (en) 2019-11-19 2021-05-27 Inscripta, Inc. Methods for increasing observed editing in bacteria
IL292895A (en) 2019-12-18 2022-07-01 Inscripta Inc Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
AU2021213705A1 (en) 2020-01-27 2022-06-16 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) * 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN111944810B (zh) * 2020-07-29 2022-05-27 中国农业大学 靶向敲除TNFα基因的sgRNA和敲除TNFα基因的猪胚胎成纤维细胞系及其应用
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
CA3204158A1 (en) 2021-01-04 2022-07-07 Juhan Kim Mad nucleases
US20240376451A1 (en) 2021-01-07 2024-11-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas
TW202400647A (zh) 2022-04-29 2024-01-01 美商普瑞諾生物科技公司 用於治療嗜酸性球驅動之疾病及病症的方法及組成物
CN118697758B (zh) * 2024-05-31 2025-10-21 河北大学 miR-128-1-5p的应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5770428A (en) * 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
US6033905A (en) 1993-04-06 2000-03-07 The United States Of America As Represented By The Department Of Health And Human Services Gibbon ape leukemia virus-based retroviral vectors
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
JPH09504429A (ja) 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
ES2285701T3 (es) 1994-11-07 2007-11-16 Human Genome Sciences, Inc. Factor-gamma de necrosis tumoral.
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
JP4440344B2 (ja) 1996-08-16 2010-03-24 シェーリング コーポレイション 哺乳動物細胞表面抗原；関連試薬
DK0961831T3 (da) 1996-08-16 2009-01-12 Human Genome Sciences Inc Humant alfa-endokin
EP0964922A4 (en) 1996-09-27 2000-10-25 Maxygen Inc METHOD FOR OPTIMIZING GENE THERAPY BY REPEATING SEQUENCE MIXING AND SELECTION
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
EP1007732B1 (en) 1997-01-17 2006-07-26 Maxygen, Inc. EVOLUTION OF procaryotic WHOLE CELLS BY RECURSIVE SEQUENCE RECOMBINATION
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
ES2284199T5 (es) 1997-01-28 2011-11-14 Human Genome Sciences, Inc. Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
DE69839668D1 (de) 1997-03-18 2008-08-14 Novozymes As Ein in-vitro-verfahren zur herstellung einer dna-bibliothek
AU6611498A (en) 1997-03-18 1998-10-12 Novo Nordisk A/S Method for constructing a library using dna shuffling
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
WO1998054202A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
EP1025208A2 (en) 1997-10-20 2000-08-09 Universita' Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
EP1690868A1 (en) 1997-10-31 2006-08-16 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
AU3289199A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Antigen library immunization
AU2674299A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
CA2327444A1 (en) 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
KR20010071613A (ko) 1998-06-29 2001-07-28 추후기재 매우 다양한 라이브러리의 생산방법
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
FR2782323B1 (fr) 1998-08-12 2002-01-11 Proteus Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
KR20010085850A (ko) 1998-09-29 2001-09-07 추후제출 코돈 변형 유전자의 재편성
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
WO2000018240A1 (en) 1998-10-01 2000-04-06 University Of Southern California Gene delivery system and methods of use
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
AU2415200A (en) 1999-01-18 2000-08-01 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1173597A1 (en) 1999-04-29 2002-01-23 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
WO2001004266A1 (en) 1999-07-08 2001-01-18 The Regents Of The Universty Of California A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
AU2001241939A1 (en) 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
WO2002022663A2 (en) 2000-09-18 2002-03-21 Maxygen, Inc. Stress resistant retroviruses
WO2002042482A2 (en) * 2000-11-27 2002-05-30 Chiron Corporation Functional lentiviral vector from an mlv-based backbone
WO2002061104A2 (en) 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
ATE439041T1 (de) * 2001-09-13 2009-08-15 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
JP2005532814A (ja) 2002-07-17 2005-11-04 ブリストル−マイヤーズ　スクイブ　カンパニー アンドロゲン応答配列の制御下にレポーター核酸を発現するトランスジェニック非ヒト哺乳動物
AU2003260769A1 (en) * 2002-09-03 2004-03-29 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
EP1649023B1 (en) 2003-07-21 2008-08-20 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
EP1819735A1 (en) 2004-11-04 2007-08-22 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
CN101065492A (zh) * 2004-11-24 2007-10-31 纳诺非科特有限公司 病毒载体
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
JP2007054069A (ja) * 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
US20090028842A1 (en) * 2005-09-30 2009-01-29 Zgene A/S Dekkera/Brettanomyces Cytosine Deaminases And Their Use
WO2007041350A2 (en) * 2005-10-01 2007-04-12 Charles Stout Regulatable fusion promoters
US8034355B2 (en) 2005-10-07 2011-10-11 Presidents And Fellows Of Harvard College Attenuated nonsegmented negative-sense RNA viruses with reduced mRNA cap methyltransferase activity comprising mutations within conserved domain VI of the large polymerase
EP1795596A1 (en) * 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
CN103642900B (zh) * 2006-01-05 2016-04-13 俄亥俄州立大学研究基金会 用于诊断和治疗实体癌的基于微小rna的方法和组合物
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
EP2004677A2 (en) 2006-03-17 2008-12-24 Aarhus Universitet Chimeric viral envelopes
AU2007241023B2 (en) * 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
ES2428067T3 (es) * 2006-07-21 2013-11-05 California Institute Of Technology Introducción selectiva de genes para la vacunación con células dendríticas
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
CN102227503B (zh) 2008-09-26 2015-10-21 托卡根公司 重组载体
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
JP5923037B2 (ja) * 2009-06-17 2016-05-24 トカジェン インコーポレーテッド 複製可能レトロウイルスベクターの産生細胞
US9187762B2 (en) 2010-08-13 2015-11-17 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Aaron Korkegian,等.Computational Thermostabilization of an Enzyme.《Science》.2005,第308卷(第5723期),857-860. *
Chien-Kuo Tai 等.Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma.《Molecular Therapy》.2005,第12卷(第5期), *
Erbs,P.等.AAG33626.1.《GenBank》.2000, *
Goffeau,A.等.NP_011996.2.《Protein NCBI》.2008, *
Hsu,Y.H.等.1UAQ_A.《Protein NCBI》.2008, *
Hu,Y.等.DQ332702.1.《GenBank》.2007, *
Korkegian,A.等.1YSB_A.《Protein NCBI》.2008, *
Miller,A.D. 等.AF010170.1.《GenBank》.2000, *
Philippe Erbs, et al..In Vivo Cancer Gene Therapy by Adenovirus-mediated Transfer of a Bifunctional Yeast Cytosine Deaminase/Uracil Phosphoribosyltransferase Fusion Gene.《Cancer Research》.2000,第60卷 *
Yanhui Hu,等.Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae.《Genome Research》.2007,第17卷(第4期),536-543页. *

Also Published As

Publication number Publication date
WO2010045002A3 (en) 2010-08-26
CN105274125A (zh) 2016-01-27
KR102025502B1 (ko) 2019-09-25
KR101724162B1 (ko) 2017-04-07
US20190185821A1 (en) 2019-06-20
JP2012503986A (ja) 2012-02-16
EP2344648A4 (en) 2012-03-14
MX2018008440A (es) 2021-06-15
EP2346995A4 (en) 2011-12-07
CN102227503A (zh) 2011-10-26
JP2015119712A (ja) 2015-07-02
EP3502256A3 (en) 2019-09-25
MX357418B (es) 2018-07-09
KR20180069131A (ko) 2018-06-22
DK2346995T3 (en) 2019-02-11
US20110217267A1 (en) 2011-09-08
IL211847A (en) 2016-11-30
MY156333A (en) 2016-02-15
IL248833A0 (en) 2017-01-31
EA027693B1 (ru) 2017-08-31
ES2709481T3 (es) 2019-04-16
IL264214B (en) 2020-01-30
JP2019141088A (ja) 2019-08-29
BRPI0919113A2 (pt) 2016-08-09
JP2012503987A (ja) 2012-02-16
CN102227501A (zh) 2011-10-26
CN105624193A (zh) 2016-06-01
WO2010045002A2 (en) 2010-04-22
EP3460061A1 (en) 2019-03-27
WO2010036986A2 (en) 2010-04-01
EP2346995A2 (en) 2011-07-27
JP2017018121A (ja) 2017-01-26
CN105624193B (zh) 2021-07-13
CN102227503B (zh) 2015-10-21
AU2009303690B2 (en) 2014-06-19
NZ592070A (en) 2012-07-27
ZA201102115B (en) 2012-07-25
EP2344648B1 (en) 2018-11-14
CA2738472A1 (en) 2010-04-22
JP6062485B2 (ja) 2017-01-18
WO2010036986A3 (en) 2010-07-01
JP2015186479A (ja) 2015-10-29
EP3502256A2 (en) 2019-06-26
US20140242033A1 (en) 2014-08-28
KR20160079149A (ko) 2016-07-05
IL264214A (en) 2019-02-28
US8722867B2 (en) 2014-05-13
JP5992548B2 (ja) 2016-09-14
IL248833B (en) 2019-01-31
JP5771147B2 (ja) 2015-08-26
AU2009303690A1 (en) 2010-04-22
KR20110063673A (ko) 2011-06-13
EP2344648A2 (en) 2011-07-20
ES2706899T3 (es) 2019-04-01
EA201790824A2 (ru) 2017-08-31
IL211847A0 (en) 2011-06-30
EA201790824A3 (ru) 2017-12-29
MX2011003039A (es) 2011-08-15
US10035983B2 (en) 2018-07-31
JP5684130B2 (ja) 2015-03-11
CO6362050A2 (es) 2012-01-20
EA201170492A1 (ru) 2011-10-31
EP2346995B1 (en) 2018-11-07
KR101870056B1 (ko) 2018-07-23
JP6523224B2 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
CN102227501B (zh) 基因治疗载体和胞嘧啶脱氨酶
KR102857378B1 (ko) ACE-tRNA에 의한 유전자 재지정을 통해 정지 코돈을 구조하는 방법
JP6014020B2 (ja) 組み換えベクターを用いたがんの治療
JP2018526007A (ja) ２ａペプチドを含む組換えベクター
CN105579581A (zh) 具有优化的a凸出物的重组载体
US7803582B2 (en) Recombinant vector and use in gene therapy
AU2013205006B2 (en) Gene Therapy Vectors and Cytosine Deaminases
US20240041957A1 (en) Retroviral vectors
JP2022507268A (ja) 結合ドメインおよび分泌可能なペプチドの遺伝子を含む組換えベクター
EP1029062A1 (en) Inhibition of human immunodeficiency virus (hiv-1) replication
WO2002064805A2 (en) Replication competent non-mammalian retroviral vectors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210720

Address after: California, USA

Patentee after: Suoyuan biomedical (USA) Co.,Ltd.

Address before: California, USA

Patentee before: Tocagen Inc.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161116

CF01 Termination of patent right due to non-payment of annual fee